View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
November 30, 2018

Deals this week: Searchlight Pharma, Q BioMed, Quest PharmaTech

Searchlight Pharma has acquired the Canadian marketing rights for Divigel® from Vertical Pharmaceuticals.

Searchlight Pharma has acquired the Canadian marketing rights for Divigel® from Vertical Pharmaceuticals .

Divigel® is a prescription transdermal estrogen product approved for the treatment of menopause-related symptoms.

Vertical Pharmaceuticals holds the marketing rights to the product in the US and has agreed to help Searchlight in launching the product in Canada.

The transaction is effective from December when Searchlight will commence distribution marketing activities for Divigel® in Canada.

The deal will enable Searchlight to provide a wide range of solutions in the women’s healthcare sector.

Based in Canada, Searchlight Pharma is a speciality healthcare company, while Vertical Pharmaceutical is a US-based pharmaceutical company with a portfolio of women’s healthcare products.

Q BioMed has entered an agreement with GE Healthcare to acquire cancer palliation therapy Metastron for an undisclosed amount.

Quest PharmaTech has entered an agreement with OncoCare Therapeutics for the development and commercialisation of its cancer therapy technology in the US.”

Q BioMed will own the brand, trademarks, and market authorisations of the drug in 22 countries, as well as all the related intellectual property. It will also receive all the market sales and distribution data from GE.

GE Healthcare will receive the transaction amount as an upfront payment. It is also entitled to receive one sales-based milestone payment and a single digit royalty payment for 15 years.

Q BioMed is a biomedical acceleration and development company, while GE Healthcare is a biotechnology company.

Both companies involved in the transaction are based in the US.

Quest PharmaTech has entered an agreement with OncoCare Therapeutics for the development and commercialisation of its cancer therapy technology in the US.

Quest will receive 45% interest in OncoCare Therapeutics as part of the agreement.

The Quest development pipeline includes two treatments, namely AR 9.6 and ACP-2127. OncoCare will collaborate with Quest on the research and development of the drug.

Canada-based Quest PharmaTech is a pharmaceutical company, while OncoCare Therapeutics is a biopharmaceutical company based in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology